SCM
MLTX icon

Soleus Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Soleus Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-400,000
Closed -$5.27M – 107
2025
Q4 		$5.27M Buy
+400,000
New +$4.72M 0.19% 66

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Soleus Capital Management's MLTX Position: Q1 2026 in Review

Soleus Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2026, closing a stake of 400,000 shares — an estimated $5.27M sold.

Soleus Capital Management first reported a position in MLTX in Q4 2025 and held it in 1 quarter. The position peaked at $5.27M in Q4 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Soleus Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Soleus Capital Management sold 400,000 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $5.27M.
  • Soleus Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2025 and held it in 1 quarter.
  • Soleus Capital Management's MoonLake Immunotherapeutics position peaked at $5.27M in Q4 2025.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.